Riskpilot← Back to searchSign inGet full accessOSLO NEVRO AS
ASActiveOrg 914539625C/O Magnat Medisinske Senter B8 Drammensveien 130, 0277 OsloMedical specialists activities · NACE 8622Est. 20141 employeesoslonevroklinikk.no
Revenue 2024
NOK 10,4M
+11% vs 2023
EBITDA margin
68.1%
+5% vs 2023
Equity ratio
93.0%
Financial strength
Net profit 2024
NOK 6,4M
0% vs 2023
| Revenue | NOK 10,4M | +11% |
| EBITDA | NOK 7,1M | +5% |
| Net profit | NOK 6,4M | +0% |
| Total assets | NOK 40,9M | +19% |
| Equity | NOK 38,1M | +16% |
| Employees | 1 | — |
Legal name
OSLO NEVRO AS
Org number
914539625
Legal form
Aksjeselskap
NACE code
8622 · Medical specialists activities
Founded
4. desember 2014
Share capital
NOK 30 000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Levere tjenester innen legevirksomhet og andre tjenester/produkter som naturlig faller sammen med dette. I tillegg vil selskapet kunne drive investeringsvirksomhet.
Address
C/O Magnat Medisinske Senter B8 Drammensveien 130, 0277 Oslo
Website
oslonevroklinikk.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 7 609 | 8 520 | 8 656 | 9 347 | 10 364 |
| Staff expenses | −1 188 | −1 128 | −1 072 | −1 114 | −1 186 |
| EBITDA | 5 407 | 6 470 | 6 535 | 6 729 | 7 061 |
| Depreciation & amort. | −70 | −80 | −228 | −271 | −291 |
| EBIT | 5 337 | 6 390 | 6 307 | 6 458 | 6 771 |
| Net financials | 222 | 797 | −418 | 1 410 | 1 206 |
| Profit before tax | 5 559 | 7 187 | 5 889 | 7 868 | 7 977 |
| Tax | 1 163 | 1 411 | 1 407 | 1 482 | 1 594 |
| Net profit | 4 396 | 5 776 | 4 482 | 6 385 | 6 383 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 19 622 | 25 554 | 28 014 | 34 429 | 40 912 |
| Equity | 18 137 | 21 914 | 26 296 | 32 681 | 38 064 |
| Long-term debt | 0 | 0 | 0 | 19 | 8 |
| Short-term debt | 1 485 | 3 640 | 1 718 | 1 729 | 2 841 |
| Total debt | 1 485 | 3 640 | 1 718 | 1 748 | 2 848 |
EBITDA margin
68.1%
This company
15.8%
Market median
+331% vs market
20202024
Equity ratio
93.0%
This company
38.2%
Market median
+143% vs market
20202024
Return on equity
16.8%
This company
18.4%
Market median
+9% vs market
20202024
Net profit margin
61.6%
This company
8.1%
Market median
+660% vs market
20202024
Asset turnover
0.25×
This company
1.12×
Market median
-78% vs market
20202024
Debt / equity
0.07×
This company
0.62×
Market median
+89% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
HB Deputy Member | Deputy Member | 2014 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairman | 2022 | |
| Former (1) | ||
| Deputy Chairman | 2022 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
OSLO NEVRO AS (this company)
Magnat Corpus Invest AsBoard members of OSLO NEVRO AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Helena Berz Slapø | Deputy Member | 0 companies |
| Andrea Gudrun Berz | Deputy Chairman | 0 companies |
| Geir Dundas Slapø | Chairman | 0 companies |